Current position

Two Sigma Investments, LP’s Bristol-Myers Squibb Co (BMY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Two Sigma Investments, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares11.54MHighest verified quarter-end share count
Quarters reported19Verified quarters with shares above zero
What happened?

Two Sigma Investments, LP first reported Bristol-Myers Squibb Co in Q3 2021. The reported position was increased and reduced across later filings. Two Sigma Investments, LP currently reports 10.09M shares. The latest verified filing showed: Sold 12.6% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 12.6% of the position−1.45M shares · 10.09M shares remained
Filing context

Quarter-end price $57.62

Q1 2026
Bought 147.4% more+6.87M shares · 11.54M shares reported after the change
Filing context

Quarter-end price $60.65

Q4 2025
Sold 14.5% of the position−791.32K shares · 4.66M shares remained
Filing context

Quarter-end price $53.94

Q3 2025
Bought 530.6% more+4.59M shares · 5.45M shares reported after the change
Filing context

Quarter-end price $45.10

Q2 2025
Bought 203.9% more+580.17K shares · 864.76K shares reported after the change
Filing context

Quarter-end price $46.29

Q4 2024
Sold 98.2% of the position−4.64M shares · 85.62K shares remained
Filing context

Quarter-end price $56.56

Portfolio importance

How important is Bristol-Myers Squibb Co in Two Sigma Investments, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.4%Q2 2026
Current rank#36of 5017 reported positions
Peak portfolio weight0.7%Q2 2022
Best historical rank#8Q2 2024
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$63.602026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$57.62Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Two Sigma’s complete trading book, models, short positions, exact trade dates or execution prices. Options are reported separately.